ATP2A1-AS1: A Potential Drug Target and Biomarker (G100289092)

Target Name: ATP2A1-AS1

NCBI ID: G100289092

ATP2A1-AS1

Other Name(s): ATP2A1 antisense RNA 1, transcript variant 1 | ATP2A1-AS1 variant 1 | ATP2A1 antisense RNA 1

ATP2A1-AS1: A Potential Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the cell's energy metabolism. It is involved in the transfer of energy from the cell's energy reserves to various cellular processes. ATP is generated from the oxidation of ADP (adenosine diphosphate) using energy from the cell's food sources. ATP has a high-energy phosphate group, which allows it to store energy for later use. This molecule is essential for many cellular processes, including muscle contractions, smooth muscle relaxation, and the transmission of signals within cells.

Mutations in the ATP gene have been linked to various human diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. The ATP gene has four splice variants: ATP2A1, ATP2A2, ATP2A3, and ATP2A4. These variants differ in the presence or absence of exon 111, which is located between exons 108 and 109 on the 3'-end of the ATP gene.

ATP2A1-AS1 is a potential drug target and biomarker for various diseases. This gene variants are associated with various health conditions, including cardiovascular disease, neurodegenerative diseases, and cancer. The altered expression of ATP2A1-AS1 has been implicated in the development and progression of these conditions.

The altered expression of ATP2A1-AS1 has been associated with various diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. For example, studies have shown that individuals with certain genetic variants, including those in the ATP2A1-AS1 gene, are at increased risk for developing cardiovascular disease. Researchers have also found that individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, have altered expression of ATP2A1-AS1.

In addition to its association with disease, ATP2A1-AS1 has also been shown to be a potential biomarker for several diseases. For example, researchers have found that individuals with certain genetic variants, including those in the ATP2A1-AS1 gene, have altered levels of ATP in their blood, which could be used as a biomarker for cardiovascular disease.

The potential drug target for ATP2A1-AS1 is related to the regulation of ATP metabolism and the function of ATP in various cellular processes. Researchers have identified several potential drug targets for ATP2A1-AS1, including modulators of ATP binding, ATP-splitting enzymes, and ATP-phosphate transporters. These drug targets could be used to treat various diseases associated with altered expression of ATP2A1-AS1, including cardiovascular disease, neurodegenerative diseases, and cancer.

In conclusion, ATP2A1-AS1 is a potential drug target and biomarker for various diseases. The altered expression of this gene has been associated with the development and progression of many diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. Further research is needed to understand the full role of ATP2A1-AS1 in these conditions and to identify potential drug targets.

Protein Name: ATP2A1 Antisense RNA 1

The "ATP2A1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP2A1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets